KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2025)

Historic Free Cash Flow for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$117.6 million.

  • Recursion Pharmaceuticals' Free Cash Flow fell 8436.83% to -$117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$447.7 million, marking a year-over-year decrease of 3473.01%. This contributed to the annual value of -$372.9 million for FY2024, which is 2439.96% down from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Free Cash Flow of -$117.6 million as of Q3 2025, which was down 8436.83% from -$79.6 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Free Cash Flow registered a high of $73.0 million during Q1 2022, and its lowest value of -$133.8 million during Q1 2025.
  • For the 5-year period, Recursion Pharmaceuticals' Free Cash Flow averaged around -$69.6 million, with its median value being -$73.7 million (2023).
  • Per our database at Business Quant, Recursion Pharmaceuticals' Free Cash Flow crashed by 144306.18% in 2021 and then surged by 24559.41% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Free Cash Flow (Quarter) stood at -$65.6 million in 2021, then grew by 19.65% to -$52.7 million in 2022, then crashed by 44.41% to -$76.1 million in 2023, then plummeted by 53.3% to -$116.7 million in 2024, then fell by 0.75% to -$117.6 million in 2025.
  • Its Free Cash Flow was -$117.6 million in Q3 2025, compared to -$79.6 million in Q2 2025 and -$133.8 million in Q1 2025.